"Total worldwide revenue was $72 million, representing growth of over 9% year-over-year."
— Jim Clemmer, CEO
03Detailed Report
ANGO
AngioDynamics Inc
Period
Q3 2025
CurrencyUSD
Report TypeQuarterly Earnings
GeneratedJun 27, 2026
Swipe to view all report sections
Executive Summary
AngioDynamics Inc reported a robust performance for the third quarter of fiscal year 2025, achieving a revenue of $72 million, reflecting a 9.2% growth year-over-year. The company's strategic emphasis on its MedTech segment propelled this growth, with a staggering 22% increase in revenue attributed to expanded product offerings. Management highlighted an increase in gross margins and positive adjusted EBITDA, underscoring the effectiveness of its operational strategies. Significant advancements in product adoption for key areas like Mechanical Thrombectomy and NanoKnife further affirm AngioDynamics' growth potential in a burgeoning healthcare market.
The management team expressed confidence in sustaining growth into the next fiscal quarters, with a revised revenue outlook pointing to a total expected revenue of $285 million to $288 million for FY 2025. This report will delve deeper into the key financial metrics, market opportunities, and the challenges that AngioDynamics faces as it navigates this dynamic landscape.
Key Performance Indicators
Revenue
Decreasing
72.00M
QoQ: -1.15% | YoY: -4.23%
Gross Profit
Increasing
38.86M
53.97% margin
QoQ: -2.63% | YoY: 19.29%
Operating Income
Increasing
-4.05M
QoQ: -61.48% | YoY: 65.08%
Net Income
Increasing
-4.41M
QoQ: 58.96% | YoY: 97.65%
EPS
Increasing
-0.11
QoQ: 57.69% | YoY: 97.64%
Revenue Trend
Margin Analysis
Financial Highlights
Revenue Performance:
- Total revenue for Q3 2025 stood at $72 million, a 9.2% increase from Q3 2024.
- MedTech revenue surged by 22%, accounting for 44% of total revenue, reflecting management's strategic focus on high-margin products.
Profitability:
- Gross profit amounted to $38.9 million, translating to a gross profit margin of 54%, an increase from the previous year.
- Adjusted EBITDA was $1.3 million, marking a notable turnaround from a loss of $3.6 million in Q3 2024.
- Net income reflected a loss of $4.4 million, with adjusted EPS improving to a loss of $0.08 per share from $0.16 in the prior year.
Balance Sheet Health:
- The company holds $44.8 million in cash and cash equivalents, supporting its operational endeavors.
- Total assets stand at $285.4 million, with total liabilities of $99.5 million, evidencing a solid capital structure.
- Current ratio at 2.21 indicates sound liquidity.
Income Statement
Metric
Value
YoY Change
QoQ Change
Revenue
72.00M
-4.23%
-1.15%
Gross Profit
38.86M
19.29%
-2.63%
Operating Income
-4.05M
65.08%
-61.48%
Net Income
-4.41M
97.65%
58.96%
EPS
-0.11
97.64%
57.69%
Key Financial Ratios
Gross Profit Margin
Good
54.00%
Gross profit margin is healthy and competitive within industry standards
Operating Profit Margin
Weak
-0.06%
Operating margin is below industry norms, profitability concerns
Net Profit Margin
Weak
-0.06%
Net profit margin is below industry norms, profitability concerns
Return on Assets
Weak
-0.02%
Return on assets suggests inefficient capital allocation
Return on Equity
Weak
-0.02%
Return on equity suggests inefficient capital allocation
Current Ratio
Healthy
2.21
Current ratio shows adequate liquidity to meet short-term obligations
Debt to Equity
Conservative
0.03
Debt-to-equity shows conservative leverage and low financial risk
P/E Ratio
Negative
-21.53x
Negative earnings make P/E ratio not meaningful
Price to Book
Fair Value
2.04x
Price-to-book ratio reasonable for profitable companies
Management Insights Available for Members
Get exclusive access to management commentary, earnings call quotes, and forward guidance from company leadership.